Glossary

22 TERMS · PLAIN LANGUAGE · SOURCED

Reviewed by Tariq Halim, MD · Last medical review: November 4, 2026 · Editorial policy

Tmax · Half-life · Steady state · Immediate release · Extended release · Delayed release · OROS · Orally disintegrating tablet · Transdermal system · Prodrug · Schedule II · Schedule III · Off-label use · Boxed warning · CYP2D6 and poor metabolizers · Generic drug · Therapeutic equivalence · Authorized generic · Bioequivalence · Orange Book · Medication Guide · Nonstimulant

Tmax (time to peak)

The time after a dose when the amount of medicine in the blood is highest. Cmax is that highest level. Prescribing information reports Tmax in its pharmacokinetics section (12.3).

Source: U.S. Food and Drug Administration. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies (pharmacokinetic parameters: Cmax, Tmax, terminal elimination half-life). FDA. U.S. Code of Federal Regulations, 21 CFR 201.57 (content and format of prescription drug labeling). eCFR.

On this site: Concerta, Ritalin

Half-life (t½)

The time it takes for the amount of a medicine in the body to fall by half. After about 4 to 5 half-lives, most of a single dose has been eliminated.

Source: Hallare J, Gerriets V. Elimination Half-Life of Drugs. StatPearls [Internet]; last updated May 3, 2025. NCBI Bookshelf NBK554498 (PMID 32119385). U.S. Code of Federal Regulations, 21 CFR 201.57 (content and format of prescription drug labeling). eCFR.

On this site: Intuniv, Strattera

Steady state

When a medicine is taken on a regular schedule, blood levels build up until the amount taken in balances the amount removed, so each day looks about the same. This usually takes about 4 to 5 half-lives.

Source: Hallare J, Gerriets V. Elimination Half-Life of Drugs. StatPearls [Internet]; last updated May 3, 2025. NCBI Bookshelf NBK554498 (PMID 32119385).

On this site: Qelbree, Kapvay

Immediate release (IR)

A form designed to dissolve and be absorbed without any intended delay or slowing. IR forms usually act quickly and wear off sooner, so they are often taken more than once a day.

Source: U.S. Food and Drug Administration. Guidance for Industry: SUPAC-MR, Modified Release Solid Oral Dosage Forms (glossary: immediate, extended and delayed release). FDA.

On this site: Ritalin, Adderall

Extended release (ER, XR, LA, CD)

A form designed to make the medicine available over a longer period, so it can be taken less often than an immediate-release form of the same medicine. Products use different release designs, so they are not interchangeable milligram for milligram unless the label says so.

Source: U.S. Food and Drug Administration. Guidance for Industry: SUPAC-MR, Modified Release Solid Oral Dosage Forms (glossary: immediate, extended and delayed release). FDA.

On this site: Concerta, Adderall XR

Delayed release

A form designed to release the medicine at a time other than right after it is taken.

Source: U.S. Food and Drug Administration. Guidance for Industry: SUPAC-MR, Modified Release Solid Oral Dosage Forms (glossary: immediate, extended and delayed release). FDA.

On this site: Jornay PM

OROS (osmotic-release tablet)

A tablet design that uses osmotic pressure to release medicine at a controlled rate: water enters through an outer membrane and pushes the medicine out through a small opening, after an outer coating gives a first, immediate dose.

Source: Relexxii (methylphenidate HCl) extended-release tablets, Prescribing Information, section 11 (Description); see the Relexxii page for the full citation.

On this site: Concerta, Relexxii

Orally disintegrating tablet (ODT)

A tablet that is placed on the tongue and allowed to break up in the mouth instead of being swallowed whole. See each product page for its handling instructions.

Source: Cotempla XR-ODT and Adzenys XR-ODT Prescribing Information, section 2 (administration); see the Cotempla XR-ODT and Adzenys XR-ODT pages for full citations. U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. FDA.

On this site: Cotempla XR-ODT, Adzenys XR-ODT

Transdermal system (patch)

A patch worn on the skin that delivers medicine through the skin into the bloodstream while it is worn.

Source: Daytrana and Xelstrym Prescribing Information (transdermal systems); see the Daytrana and Xelstrym pages for full citations. U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. FDA.

On this site: Daytrana, Xelstrym

Prodrug

An inactive form of a medicine that the body converts into the active medicine. Lisdexamfetamine (Vyvanse) is converted to dextroamphetamine; serdexmethylphenidate (in Azstarys) is converted to dexmethylphenidate.

Source: Vyvanse and Azstarys Prescribing Information, section 12.1 (lisdexamfetamine and serdexmethylphenidate are prodrugs); see the Vyvanse and Azstarys pages for full citations.

On this site: Vyvanse, Azstarys

Schedule II (CII) controlled substance

A U.S. Drug Enforcement Administration category for medicines with accepted medical use and a high potential for abuse, with use potentially leading to severe psychological or physical dependence. The DEA lists Adderall, Dexedrine and Ritalin as examples. Prescribing information states the schedule in section 9.1.

Source: U.S. Drug Enforcement Administration. Drug Scheduling. DEA. U.S. Code of Federal Regulations, 21 CFR 201.57 (content and format of prescription drug labeling). eCFR.

On this site: Adderall, Ritalin

Schedule III (CIII) controlled substance

A U.S. Drug Enforcement Administration category for medicines with a potential for abuse less than Schedule I and II drugs, a currently accepted medical use, and abuse that may lead to moderate or low physical dependence or high psychological dependence. On this site, centanafadine (Simtriyo) is Schedule III: the DEA placed it there by an interim final rule effective October 30, 2026.

Source: Drug Enforcement Administration. Schedules of Controlled Substances: Placement of Centanafadine in Schedule III (interim final rule; criteria of 21 U.S.C. 812(b)(3)). 91 FR 68470, Oct 30, 2026. Federal Register. U.S. Drug Enforcement Administration. Drug Scheduling. DEA.

On this site: Simtriyo

Off-label use

Use of an FDA-approved medicine in a way the label does not cover, such as for a different condition, in a different form, or at a different dose. Clinicians may prescribe off-label when they judge it medically appropriate, but the FDA has not determined that the medicine is safe and effective for that use. This site tags off-label evidence separately.

Source: U.S. Food and Drug Administration. Understanding Unapproved Use of Approved Drugs “Off Label”. FDA.

On this site: Off-label tagging policy

Boxed warning

A warning printed inside a box at the top of the prescribing information for serious risks, particularly those that may lead to death or serious injury. Stimulant labels carry a boxed warning about abuse, misuse and addiction; atomoxetine’s is about suicidal thoughts in children and teens.

Source: U.S. Code of Federal Regulations, 21 CFR 201.57 (content and format of prescription drug labeling). eCFR.

On this site: Vyvanse, Strattera

CYP2D6 and poor metabolizers

CYP2D6 is a liver enzyme that breaks down some medicines, including atomoxetine. People whose genes give them little CYP2D6 activity (poor metabolizers), or who take a medicine that strongly blocks it, have higher and longer-lasting levels, which is why some labels give different titration advice for them.

Source: Strattera (atomoxetine) Prescribing Information, sections 2.5 and 12.3 (CYP2D6 poor metabolizers); see the Strattera page for the full citation.

On this site: Strattera, Atoncy

Generic drug

A copy of a brand-name medicine that is the same in active ingredient, strength, dosage form, how it is taken and intended use, though inactive ingredients can differ. Before approval the maker must show it is bioequivalent to the brand.

Source: U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. FDA. U.S. Food and Drug Administration. FDA List of Authorized Generic Drugs (“Is an Authorized Generic Drug the Same Thing as a Generic Drug?”). FDA.

On this site: Concerta

Therapeutic equivalence (AB, AA ratings)

FDA codes in the Orange Book showing whether a product is expected to have the same clinical effect and safety as the reference product. Codes beginning with “A” (such as AA or AB) mean therapeutically equivalent; codes beginning with “B” mean not rated equivalent.

Source: U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. FDA.

On this site: Ritalin, Relexxii

Authorized generic

The brand-name product sold without the brand name on its label, by the brand company or with its permission. It is the same drug product as the brand (a tablet or capsule may look different), and because it is sold under the brand’s approval it is not listed in the Orange Book.

Source: U.S. Food and Drug Administration. FDA List of Authorized Generic Drugs (“Is an Authorized Generic Drug the Same Thing as a Generic Drug?”). FDA.

On this site: Cotempla XR-ODT, Atoncy

Bioequivalence

Two products are bioequivalent when the medicine gets to where it works in the body at the same time and in the same amount. A generic must show bioequivalence to its reference product to be approved.

Source: U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. FDA. U.S. Food and Drug Administration. FDA List of Authorized Generic Drugs (“Is an Authorized Generic Drug the Same Thing as a Generic Drug?”). FDA.

On this site: Arynta, Adzenys XR-ODT

Orange Book

The FDA’s list of approved drug products with therapeutic equivalence evaluations. Its formal title is Approved Drug Products With Therapeutic Equivalence Evaluations. This site uses it for generic availability and equivalence codes.

Source: U.S. Food and Drug Administration. FDA List of Authorized Generic Drugs (“Is an Authorized Generic Drug the Same Thing as a Generic Drug?”). FDA. U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. FDA.

On this site: Source hierarchy

Medication Guide

FDA-approved information written for patients on how to use a medicine safely.

Source: U.S. Food and Drug Administration. Drugs@FDA Glossary of Terms. FDA.

On this site: Concerta

Nonstimulant

On this site, an ADHD medicine that is not a stimulant and not a controlled substance: atomoxetine, viloxazine, guanfacine ER and clonidine ER. Centanafadine (Simtriyo) is listed separately because its label classifies it as a CNS stimulant.

Source: Simtriyo (centanafadine) Prescribing Information; see the Simtriyo page for the full citation and the class wording.

On this site: Nonstimulants, Newer mechanism

EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. See the medical disclaimer.